Abstract:Introduction: t(16;21)(p11;q22)/ FUS::ERG is a rare recurrent abnormality in acute myeloid leukemia (AML) and confers a poor prognosis in AML patients. Previous studies analyzed the role of allogeneic hematopoietic stem cell transplantation (HSCT) in these patients but the results were discordant. AML is characterized by concurrent mutations, which cooperated in the leukemogenesis and refractory/relapse mechanism. However, few studies described the mutational landscape of FUS::ERG AML. Olshanskaya et al. discovered concomitant DNMT3A, ASXL1, RUNX1 and BCOR mutations in the FUS::ERG AML patients but the study was limited to the small case number. Therefore, we aim to assess genomic alterations and clinical outcome of FUS::ERG AML patients with a larger cohort. Methods: We reviewed medical records of 12328 AML patients diagnosed between December, 2011 and February, 2022 in our hospital. A total of 39 consecutive AML patients with karyotype or reverse transcription-polymerase chain reaction analysis proven t(16;21)(p11;q22)/ FUS::ERG were identified. Whole exome sequencing was performed in 4 patients and targeted sequencing was performed in 20 patients. Patients with follow-up time longer than 30 days were included in the survival analysis. Overall survival (OS) was calculated from the date of diagnosis to the date of death or censoring. Event free survival (EFS) was calculated from the date of diagnosis to the date of refractory, relapse, death or censoring, whichever came first. Results: M5 was the predominant subtype according to French-American-British classification systems. CD56 (91.9%) and CD123 (81.1%) were found to be expressed in most FUS::ERG AML patients. Six patients had central nervous system involvement diagnosed by flowcytometry (FCM) analysis of cerebrospinal fluid at the time of first lumbar puncture. One patient was diagnosed central nervous system involvement at relapse (Table 1). The most prevalent somatic variants of our FUS::ERG AML patients were PTPN11 (25%), NRAS (20%), RELN (15%), CENPB (10%), RUNX1 (10%) and SH2B3 (10%) mutations (Figure 1). Five patients had no somatic mutation detected by targeted sequencing. Notably, RTK-RAS signaling pathway was the most involved pathway after clustering the aberrated genes according to the Gene Ontology terms, which included PTPN11, NRAS, ABL1 and JAK2 aberrations. All but one PTPN11 mutations affected the amino terminal (N)-SH2 domain. NRAS mutation were found mutated at amino acid G12 and Q61. The median EFS of the patients was 9.3 months (95% CI: 9.2-NA) and OS was 18.2 months (95%CI: 13.1-NA). Due to the poor outcome of this subtype of AML, allogeneic HSCT was highly recommended. A total of 14 patients underwent allogeneic HSCT. Notably, seven of ten patients were positive for minimal residual disease assessed by FCM at the time of transplantation. We did not observe the statistically significant effect of HSCT on improving the EFS (p = 0.24) or OS (p=0.26) of our patients. Conclusions: PTPN11 and NRAS were the most frequent mutations and RTK-RAS signaling pathway was the most involved pathway in rare AML patients with t(16;21)(p11;q22)/ FUS::ERG. The addition of signaling pathway inhibitors followed by HSCT might be an effective strategy to overcome the dismal outcome of this subtype. Larger cohort studies are warranted to investigate the molecular characteristics further as well as evaluate the clinical activity of the SHP2 (PTPN11) inhibitors in FUS::ERG AML patients.

Mutated ASXL1 Upregulates Mtor Expression in Renal Cell Carcinoma with Fibromyomatous Stroma

Wide morphological spectrums of renal neoplasms with TSC/mTOR, NF2, or monoallelic MUTYH germline mutation

Recurrent MTOR Mutations in Renal Cell Carcinoma With Fibromyomatous Stroma: A Report of 2 Tumors

Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (Rccs)

Nuclear Translocation of ASPL-TFE3 Fusion Protein Creates Favorable Metabolism by Mediating Autophagy in Translocation Renal Cell Carcinoma.

Analysis of clinicopathological and molecular features of ELOC(TCEB1) -mutant renal cell carcinoma

TSC/MTOR-associated Eosinophilic Renal Tumors Exhibit Heterogenous Clinicopathologic Spectrums: A Targeted Next-generation Sequencing and Gene Expression Profiling Study

Fumarate Hydratase–Deficient Renal Cell Carcinoma With Predominant Tubulocystic Features Mimics Tubulocystic Renal Cell Carcinoma

Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas

CRTC1–SS18 Fusion Sarcoma with Aberrant Anaplastic Lymphoma Kinase Expression

SFPQ/PSF-TFE3 Renal Cell Carcinoma: a Clinicopathologic Study Emphasizing Extended Morphology and Reviewing the Differences Between SFPQ-TFE3 RCC and the Corresponding Mesenchymal Neoplasm Despite an Identical Gene Fusion.

TFE3 Fusions Escape from Controlling of Mtor Signaling Pathway and Accumulate in the Nucleus Promoting Genes Expression in Xp11.2 Translocation Renal Cell Carcinomas.

Novel Gene Fusion of PRCC-MITF Defines a New Member of MiT Family Translocation Renal Cell Carcinoma: Clinicopathological Analysis and Detection of the Gene Fusion by RNA Sequencing and FISH.

MED15 :: TFE3 fusion renal cell carcinoma with extensive cystic change: A clinicopathologic and molecular genetic study of 2 cases, with an emphasis on differential diagnosis

The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma

Gene fusion analysis in renal cell carcinoma by FusionPlex RNA‐sequencing and correlations of molecular findings with clinicopathological features

RTK-RAS Signaling Pathway Was Enriched in Rare Acute Myeloid Leukemia Patients with T(16;21)(p11;q22)/ FUS::ERG

[Eosinophilic Solid and Cystic Renal Cell Carcinoma: Clinicopathological Analysis and Molecular Characterization].

Genomic Alterations and Tumor Mutational Features of Chinese Xp11.2 Translocation Renal Cell Carcinoma Patients

EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma

Renal Cell Carcinomas with T(6;11)(p21;q12) Presenting with Tubulocystic Renal Cell Carcinoma-Like Features.